EMERGING RESEARCHER APPOINTED TO JAMES PACKER CHAIR IN MOOD DISORDERS AT UNSW Joins department with over 60 years research in Psychiatry and Mental Health to investigate Bipolar Disorder
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney.
Professor Dean spoke about UNSW being home to an outstanding mental health research community with key partners across the Mindgardens Neuroscience Network, welcoming Dr Ratheesh
As a leading clinical researcher in mood and psychotic disorders, Dr Ratheesh is passionate about prompt and early access to interventions for people with such conditions.
The appointment comes after prominent businessman and investor James Packer, jointly with The Packer Family Foundation, made a $7 million gift to establish the role last year.
The Chair will lead a new unit at UNSW and the Mindgardens Neuroscience Network that will conduct rigorous research in mental health, with a particular focus on mood disorders such as bipolar disease. The gift also funds a team of researchers to support the Chair.
Dr Ratheesh’s research is focused on understanding pathways leading to the onset of mood disorders and finding ways to provide effective treatments for individuals who develop such conditions. He has worked as a psychiatrist for over 12 years both in youth and adult mental health settings and has led several studies that have helped identify risk markers for future bipolar disorder.
He believes some of the current knowledge gaps in mood disorders include our ability to predict who will develop such conditions, who is at risk of worsening, and who will respond to specific treatments.
Dr Ratheesh currently leads an NHMRC Partnership grant in early intervention for bipolar disorder and is a chief investigator on a Centre of Research Excellence grant in early intervention for bipolar disorder. He co-leads the International Society of Bipolar Disorders Taskforce on Early Intervention and is an Associate Editor for the leading journal, the Australian and New Zealand Journal of Psychiatry. He has received awards from the International Early Psychosis Association and the Australasian Society for Bipolar and Depressive Disorders for his research.
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
-
Strategic research investments for health and prosperity
The CEO of Research Australia, Nadia Levin spoke with Australian Health Journal about the following:
– Current medical research and development landscape in Australia
– Investment required to support the Health and Medical Research and Innovation pipeline
– The National Medical Products Industry Plan and its impact on the Australian economy
– The Health and Medical Research WorkforceIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
